Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients
Hepatocellular carcinoma (HCC) ranks as a leading cause of common cancer and cancer-related death. The major etiology of HCC is due to chronic hepatitis virus including HBV and HCV infections. Scheduled HCC surveillance in high risk populations improves the early detection rate and the feasibility o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/7/1729 |
| _version_ | 1797538708440743936 |
|---|---|
| author | Wei Teng Yen-Chun Liu Wen-Juei Jeng Chien-Wei Su |
| author_facet | Wei Teng Yen-Chun Liu Wen-Juei Jeng Chien-Wei Su |
| author_sort | Wei Teng |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) ranks as a leading cause of common cancer and cancer-related death. The major etiology of HCC is due to chronic hepatitis virus including HBV and HCV infections. Scheduled HCC surveillance in high risk populations improves the early detection rate and the feasibility of curative treatment. However, high HCC recurrence rate still accounts for the poor prognosis of HCC patients. In this article, we critically review the pathogenesis of viral hepatitis-related hepatocellular carcinoma and the evidence of tertiary prevention efficacy by current available antiviral treatment, and discuss the knowledge gap in viral hepatitis-related HCC tertiary prevention. |
| first_indexed | 2024-03-10T12:35:13Z |
| format | Article |
| id | doaj.art-d44842e63cf44d598b4824ec0db0dde8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T12:35:13Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d44842e63cf44d598b4824ec0db0dde82023-11-21T14:19:57ZengMDPI AGCancers2072-66942021-04-01137172910.3390/cancers13071729Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected PatientsWei Teng0Yen-Chun Liu1Wen-Juei Jeng2Chien-Wei Su3Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, TaiwanDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, TaiwanDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taiwan. No.201, Sec. 2, Shipai Rd., Peitou District, Taipei 11217, TaiwanHepatocellular carcinoma (HCC) ranks as a leading cause of common cancer and cancer-related death. The major etiology of HCC is due to chronic hepatitis virus including HBV and HCV infections. Scheduled HCC surveillance in high risk populations improves the early detection rate and the feasibility of curative treatment. However, high HCC recurrence rate still accounts for the poor prognosis of HCC patients. In this article, we critically review the pathogenesis of viral hepatitis-related hepatocellular carcinoma and the evidence of tertiary prevention efficacy by current available antiviral treatment, and discuss the knowledge gap in viral hepatitis-related HCC tertiary prevention.https://www.mdpi.com/2072-6694/13/7/1729carcinogenesiscirrhosisdirect acting antiviral agentsinterferonnucleos(t)ide analoguessustained virologic response |
| spellingShingle | Wei Teng Yen-Chun Liu Wen-Juei Jeng Chien-Wei Su Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients Cancers carcinogenesis cirrhosis direct acting antiviral agents interferon nucleos(t)ide analogues sustained virologic response |
| title | Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients |
| title_full | Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients |
| title_fullStr | Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients |
| title_full_unstemmed | Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients |
| title_short | Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients |
| title_sort | tertiary prevention of hcc in chronic hepatitis b or c infected patients |
| topic | carcinogenesis cirrhosis direct acting antiviral agents interferon nucleos(t)ide analogues sustained virologic response |
| url | https://www.mdpi.com/2072-6694/13/7/1729 |
| work_keys_str_mv | AT weiteng tertiarypreventionofhccinchronichepatitisborcinfectedpatients AT yenchunliu tertiarypreventionofhccinchronichepatitisborcinfectedpatients AT wenjueijeng tertiarypreventionofhccinchronichepatitisborcinfectedpatients AT chienweisu tertiarypreventionofhccinchronichepatitisborcinfectedpatients |